Figure 11.

Novel topical formulation of Fenoldopam eliminates preferentially, or reduce profoundly the size of, >90 of % big alive normal human T cells within 48 hr, while sparing most of the small alive T cells. See the corresponding FACS images in Fig 10 and the figure legend describing the experimental groups, and the different subpopulation of T cells. (a–c) Number of resting T cells: either of all resting T cells (a), or only of the small alive resting T cells (b), or only of the big alive resting T cells (c). (d–f) Number of activated T cells: either all activated T cells (d), or only of the small alive activated T cells (e), or only of the big alive activated T cells (f). The numbers represent mean and SD of three independent experiments (n = 3).